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ABSTRACT 
International Journal of Exercise Science 10(7): 1029-1037, 2017. Notwithstanding 
the lack of exercise research, several reviews have championed the use of melatonin to combat 
metabolic syndrome. Therefore, this study compared substrate utilization during a 30-minute 
(min) graded exercise protocol following the ingestion of either 6 mg melatonin (M) or a placebo 
(P). Participants (12 women, 12 men) performed stages 1-5 of the Naughton graded exercise 
protocol (6 min per stage). The protocol was repeated 4 times (2x M, 2x P) at the same time of day 
with one week separating each session. Expired gases were monitored, VO2 and respiratory 
exchange ratio (RER) output was provided every 30s. Total, carbohydrate (CHO), and fat energy 
expenditures were obtained from the RER values using the formulae of Lusk. The VO2 at which 
CHO accounted for 50% of the total caloric expenditure was calculated by a VO2: RER regression 
line. Additionally, the energy derived was calculated by multiplying VO2 and the respective 
energy expenditures. Then, the total, CHO, and fat energies consumed during the 30 min of 
exercise were determined by calculating the area under the kJ/min: time curve using the 
trapezoid rule. The final data for the two similar trials were averaged and a paired-T test was 
used for statistical comparison. The average VO2 for 50% CHO usage was significantly lower 
following M (0.84 ± 0.54 l·min-1) than after P (1.21 ± 0.52 l·min-1). Also, average CHO kJ for M (627 
± 284) was significantly (p < 0.004) greater than P (504 ± 228), and accounted for a significantly 
greater contribution of total kJ consumed (M = 68% ±15 vs. P = 61% ± 18). Ingestion of melatonin 
30 min prior to an aerobic exercise bout elevates CHO use during exercise. 
 
KEY WORDS: Carbohydrate metabolism, metabolic syndrome, cross-over point, 
caloric expenditure 
 
INTRODUCTION 
 
Metabolic syndrome clusters several metabolic abnormalities, including central (intra-
abdominal) obesity, dyslipidemia (high cholesterol and blood lipids), hyperglycemia (high 
blood glucose), insulin resistance and hypertension (10, 21, 32). The ultimate importance of 
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this cluster is to identify individuals at high risk for type 2 diabetes, cardiovascular disease, 
and strokes (10, 21, 32). Since metabolic syndrome is an interaction between several different 
disease states, numerous causative mechanisms leading to metabolic syndrome have been 
identified. The major factors identified include (but not limited to) inactivity, obesity, elevated 
circulating inflammatory and/or thrombotic markers (C-reactive protein, tumor necrosis 
factor-α (TNF- α), interleukin-6, and plasminogen activator inhibitor type 1), reduced anti-
inflammatory molecules (adiponectin), excessive oxidative stress (too few anti-oxidants 
and/or too many reactive oxygen species), and growth hormone deficiency (10, 21, 32). In 
addition, recent evidence has emerged to suggest that alterations in circadian systems and 
sleep participate in the pathogenesis of the disease (24). 
 
It is possible to prevent or delay the onset of metabolic syndrome by reducing lifestyle risk 
factors through moderate weight loss and increased physical activity (10, 12, 16, 21, 27). 
Several studies have shown that lifestyle changes that include exercise can significantly delay 
and possibly prevent this disease (12, 21, 27). Along with exercise, some experts have 
championed melatonin (8, 20, 22, 39) as a chemical that can possibly help with alleviating the 
symptoms of metabolic syndrome and its related diseases. Melatonin (N-acetyl-5-
methoxytryptamine) is a hormone primarily produced by the pineal gland, but is also 
synthesized in the retina, kidneys, digestive tract, and leucocytes (1, 11, 22). Over the past ten 
years, melatonin has been the focus of considerable attention, albeit most of the attention is 
due to its function as a sleep aid or to improve circadian rhythm. Current internet search 
engine queries return numerous websites devoted to espousing the benefits of melatonin. In 
addition to its faddish appearance, mounting evidence in published in peer-reviewed scientific 
journals provides evidence of improving metabolic risk factors from exogenous melatonin (1, 
8, 9, 16, 11, 20, 28, 38, 40). All of this research suggests that melatonin has crucial roles in 
various metabolic functions in addition to its role as an anti-oxidant (11, 20, 39), anti-
inflammatory (1, 9, 16, 40), chronobiotic (4, 24), and growth hormone regulator (22, 26, 29). 
  
Despite the numerous research studies on melatonin’s influence on the aforementioned facets 
of metabolic syndrome, the influence of exogenous melatonin upon the levels of blood glucose 
and lipids and their interplay with exercise have not been extensively studied, and 
inconsistent data have been published concerning melatonin’s influence on substrate 
utilization. For instance in animal studies, exogenous melatonin increases blood glucose in 
pigeons (17), but in rats melatonin can have either no influence on plasma glucose levels (18, 
19) or it can cause increases in blood glucose (25, 35). In two studies where aerobic exercise to 
exhaustion was performed, muscle and liver glycogen content were significantly higher in 
melatonin-treated exercised animals compared to untreated exercised animals (25, 35). Also 
with acute aerobic exercise, plasma and liver lactate (18), plasma free fatty acid and plasma 
beta-hydroxybutyrate were significantly reduced (3, 19, 28). Melatonin-increased lipid 
utilization has also been reported in Japanese quail (41). In more germane studies, when mice 
were fed melatonin along with a high-fat diet, they had better control of blood glucose levels 
(37). Similarly, oral melatonin reduced fasting hyperglycemia in male Zucker diabetic fatty 
(ZDF) rats (2). Thus, it remains unclear how exogenous melatonin affects blood glucose or 
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blood lipids and if melatonin’s effects upon these factors have a direct effect upon metabolic 
outcomes.  
 
Similar to the animal research, the influence of exogenous melatonin on humans has not been 
extensively studied, and inconsistent data have been published. For instance, Peschke et al. 
(33) noted that during the night, diabetic patients have lower elevations in nighttime 
melatonin levels but higher blood glucose levels. The authors interpreted these occurrences as 
a possible relationship between low melatonin and hyperglycemia during sleep (33). On the 
other hand, Radziuk and Pye (34) showed that the nocturnal rise in blood glucose and 
endogenous glucose production seen in people with type 2 diabetes coincides with an increase 
in melatonin. In addition, two studies have shown promise for the use of melatonin as a 
therapeutic agent for Type 2 diabetes. In one study, Hussain et al. (15) gave melatonin and zinc 
acetate, alone or in combination with metformin. They found that when compared to a 
placebo, the aforementioned treatments improved fasting and postprandial glycemic control 
and lowered glycosylated hemoglobin (HbA1c) concentration (15). Additionally, Garfinkel et 
al. (13) found that long-term administration of prolonged-release melatonin resulted in lower 
HbA1c levels. In contrast to the two aforementioned studies, Cagnacci and associates (6) found 
that after ingesting melatonin, post-menopausal women had both reduced glucose usage and 
reduced insulin sensitivity. Additionally, a reduction in blood glucose clearance was seen 
following ingestion of melatonin (31). Changes in human exercise substrate utilization with 
exogenous melatonin, however, are poorly understood with only Sanders et al. (36) reporting 
that blood glucose levels during graded exercise were higher following the ingestion of 
melatonin. 
 
Thus, notwithstanding the claims of different review articles (8, 20, 39), it would appear that 
exogenous melatonin usage to ameliorate metabolic syndrome is not wholly supported by 
human research. Unfortunately, information about the relationship in humans between 
melatonin and the most widely recommended therapeutic treatment, physical exercise, is still 
lacking. Therefore, the purpose of this research study was to further the information on 
melatonin by evaluating substrate utilization during graded exercise with and without 
exogenous melatonin. Since exercise intensity has an influence on substrate utilization, it was 
decided that the initial study would look at the carbohydrate and lipid utilization ‘crossover 
point’ (i.e. the workload where carbohydrate usage exceeds 50% of the total caloric 
consumption. 
 
METHODS 
 
Participants 
Twelve males (24 ± 2.4 yrs; 176 ± 4.8 cm; 85.1 ± 17.8 kg) and twelve females (24 ± 1.1 yrs; 167 ± 
7.4 cm; 63.6 ± 6.5 kg) who were enrolled in graduate Kinesiology classes at Louisiana State 
University (LSU) were recruited to participate in this project. All participants were healthy, 
non-smoking college students, and were not taking any medications. To be considered for this 
investigation, each participant had to have engaged in a minimum of 30 min of either resistive 
or endurance exercise (or both) 3 days per week for the preceding six months. The study was 
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approved by the LSU institutional review board, and each subject submitted both written and 
oral consent before engaging in the experiment. 
 
Protocol 
A randomized balanced crossover design was used to test the acute effects of melatonin. Each 
participant was tested a total of four times after ingesting either 6 mg of melatonin (twice) or a 
placebo consisting of 50 mg of methylcellulose (twice). The experimental design was double-
blind in addition to placebo controlled. One week separated each treatment, and all 
measurements were made at the same time of day. Prior to each visit, the subjects were asked 
to refrain from exercise for 24 h and to maintain their same dietary practices. All tests were 
performed before 11 am. Prior to each test, the subjects were asked to consume their normal 
breakfast one hour before their scheduled test time, and to eat that same breakfast prior to 
each test. Thirty minutes following the ingestion of melatonin or placebo, the substrate 
utilization tests began.  
 
The participants reported to the laboratory one hour postprandial. One of the two treatment 
pills was ingested and the subject sat quietly for 30 minutes. After the rest period, the 
participants started walking on the treadmill using the Naughton protocol (30). The 
participants began at stage 1, and walked for six minutes at each stage, during which 
expiratory gases were collected using a Parvo Medics TrueOne 2400 metabolic cart (Sandy, 
UT, USA). This continued until five stages were completed (30 min). 
 
The expired gases obtained during the graded exercise protocol were used to calculate oxygen 
consumption, carbon dioxide production, and respiratory exchange ratio (RER). To determine 
the ‘crossover point’, the VO2 (l·min-1) at which CHO accounted for 50% of the energy 
expended was calculated. To obtain this value, participants’ VO2 (l·min-1) values and the 
percentage of CHO being used (obtained from the RER using the formulae of Lusk (23)) for 
each 15s of exercise were plotted against each other (VO2 on the y-axis). A regression line was 
derived for this plot and the regression formulae were used to calculate the VO2 values when 
CHO use was at 50% of the total caloric expenditure. 
 
In addition, the total calories from CHO and the relative percentage of CHO utilized during 
each six minute exercise stage were determined. This was calculated by plotting the product of 
VO2 (l·min-1) and the respective energy expenditure (total, and CHO kJ·min-1) for each 15s of 
exercise. The area under the kJ: time curve was then calculated using the trapezoid rule (14). 
The total and CHO calories utilized were obtained from the RER using the formulae of Lusk 
(23). 
 
Statistical Analysis 
The dependent variables analyzed were VO2 at 50% CHO as well total energy expended, total 
energy derived from CHO, and total relative energy derived from CHO (CHO * Total-1). For 
both the whole test (all 5 stages) and each individual stage, the values for the two tests 
performed with the same supplement were averaged and these averages were used for 
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analysis. A paired T-test was used to determine if a difference existed between the melatonin 
and placebo conditions’ dependent variables. The level of significance was set at p < 0.05. 
 
RESULTS 
 
For the ‘crossover point’, there was a significant difference (p < 0.001) between the average 
VO2 (l·min-1) at which the participants achieved 50% CHO usage after P (1.21 ± 0.52 l·min-1) 
compared to M (0.84 ± 0.54 l·min-1). Average CHO expended (kJ) for all five stages as well as 
for the total 30 minutes are presented in Figure 1. Average CHO expenditure after melatonin 
(M) ingestion for the total work period as well as for stages 2-5 were significantly (p < 0.05) 
greater than after the placebo (P) ingestion. There was no significant difference in CHO 
expenditure between M and P during stage 1. 
 
 
Figure 1.  The average CHO expenditure for the entire 30 min of work as well as for Naughton Stages 1-5 after 
either placebo or melatonin ingestion. * indicates a CHO expenditure following melatonin ingestion that is 
significantly greater (p < 0.05) than following placebo ingestion. 
 
Figure 2 shows the relative contribution CHO made of the total kJ consumed. The relative 
contribution CHO made of the total kJ consumed for the entire 30 min of work as well as for 
stages 3-5 after melatonin (M) ingestion were significantly (p < 0.05) greater than after the 
placebo (P). There was no significant difference between M and P during Stages 1 & 2. 
 
DISCUSSION 
 
As mentioned above, notwithstanding the promotion of exogenous ingestion of melatonin as a 
treatment for metabolic syndrome (8, 20, 39), research data has not been completely 
supportive. For example, resting human studies have been contraindicative, with some 
researchers showing a relationship between melatonin and low blood glucose (13, 15), and 
others showing melatonin to be related to higher blood glucose levels (6, 31, 34). With respect 
to exercise, changes in human exercise substrate utilization with exogenous melatonin, 
however, are few with only Sanders et al. (36) reporting that blood glucose levels during 
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graded exercise were higher following glucose ingestion. Therefore, the intent of this study 
was to supply initial information concerning the effect of melatonin on substrate utilization 
during graded exercise. This study showed that when physically active adults ingested 
melatonin 30 min prior to aerobic exercise, the predominant reliance upon CHO (Figure 2) to 
fuel the exercise occurred at a lower exercise intensity than following placebo ingestion. This 
earlier switch to CHO resulted in an increase in the total amount of CHO used during the 
exercise (Figure 1). Thus, it would appear that melatonin ingestion prior to exercise could 
enhance the anti-metabolic syndrome actions of exercise by decreasing any overabundance of 
blood glucose via increased usage. 
 
 
Figure 2.  The relative contribution from CHO to the total kJ consumed for the entire 30 min of work as well as for 
Naughton Stages 1-5 after either placebo or melatonin ingestion. * indicates a relative contribution from CHO 
following melatonin ingestion that is significantly greater (p < 0.05) than following placebo ingestion. 
While an increase in the removal and usage of blood glucose is desirable, before it can be 
conclusively stated that the coupling of melatonin ingestion with exercise would benefit 
individuals with metabolic syndrome, one must determine why melatonin increased CHO 
usage. It is well documented that increased blood glucose levels during exercise leads to 
enhanced glucose usage (7), and it is likely that the increased use of CHO is due a rise in blood 
glucose levels triggered by the ingestion of melatonin. As mentioned above, resting human 
studies have shown melatonin to be related to higher blood glucose levels (6, 31, 34). 
Moreover, long-term oral melatonin led to elevated plasma glucagon in Wistar rats, and this 
effect appeared to be greater when the rats were hyperglycemic (5). Additionally, Cagnacci et 
al. (6) showed that the raised blood glucose post-melatonin ingestion persisted for at least 180 
min. Thus, it would appear that the increased use of glucose shown in this study was due a 
melatonin-induced elevation of blood glucose concentration. 
 
In summary, the results of this study show that when melatonin is ingested by young active 
healthy individuals prior to exercise, there is an increased use of glucose as a fuel for the 
exercise. Unfortunately, the melatonin-induced increased use of glucose cannot ensure that a 
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melatonin and exercise program will result in lower blood glucose post exercise. This is 
because the increased use of glucose was probably due to a melatonin-influenced rise in 
overall blood glucose levels. Therefore, caution should be placed upon the increased use of 
CHO during exercise as an example of melatonin benefiting individuals with metabolic 
syndrome. Rather this finding may point to a negative relationship between melatonin 
ingestion and metabolic syndrome. If the increased use of CHO is due to a melatonin induced 
increase in blood glucose, then it would be advisable to be engaged in exercise as soon as 
possible after the ingestion of the melatonin. Especially if that person is using melatonin to 
combat metabolic syndrome. Considering that our investigation only included 20-30 year old 
participants, future research could investigate those of middle age, poor fitness levels or those 
with Type 2 Diabetes. Since high melatonin encourages greater blood glucose use, it may be 
possible for those with Type 2 Diabetes to have a different response to exercise to aid in 
lowering blood glucose if they were to exercise in the morning as opposed to the 
evening/night. Additionally, future research investigating melatonin and blood glucose levels 
could incorporate individuals such as shift workers or patients with sleep disorders/sleep 
deprivation. Utilizing those types of participants may help to provide some insight on 
potential mechanisms responsible for the metabolic dysregulation within these populations.  
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